RxDoctor Payments Data

Michael Russo, MD

Family Medicine · Marrero, LANPI 1194887125

Payments from drug & device makers

$10,984in general payments, 2019–2025

Across 621 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • GSK$818
  • Bayer$773
  • Sunovion Pharmaceuticals Inc.$716
  • Novo Nordisk$441
  • plus $5K from 50 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$10,89499%
  • Education$721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,984 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$400,770
Medicare patients
214
Services billed
4,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban323$135,452
OzempicSemaglutide114$109,591
MounjaroTirzepatide90$97,834
FarxigaDapagliflozin Propanediol103$64,096
TrulicityDulaglutide86$50,743
JanuviaSitagliptin Phosphate167$47,610
XareltoRivaroxaban92$46,155
KerendiaFinerenone47$31,500
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$29,621
LinzessLinaclotide50$29,376
TradjentaLinagliptin93$29,106
TivicayDolutegravir Sodium24$26,801
VraylarCariprazine Hcl13$21,662
Trijardy XrEmpaglifloz/Linaglip/Metformin30$20,727
JardianceEmpagliflozin43$19,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$249$148,577176 claims
PfizerEliquis$155$135,452323 claims
Novo NordiskOzempic$441$109,591114 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,378$93,716141 claims
Boehringer IngelheimTradjenta, Trijardy Xr, Jardiance$280$68,956166 claims
AbbVieLinzess, Vraylar$2,023$51,03963 claims
MerckJanuvia$192$47,610167 claims
Johnson & JohnsonXarelto$344$46,15592 claims
BayerKerendia$773$31,50047 claims
GSKAnoro Ellipta, Trelegy Ellipta$818$22,01229 claims
UCB, Inc.Nayzilam$201$11,54717 claims
NovartisEntresto$217$7,69314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →